KDR and osteosarcoma: Apatinib is a novel and high selectivity inhibitor of the vascular endothelial growth factor receptor-2 (VEGFR2) tyrosine kinase, which will block the downstream signal transduction of VEGFR2 at the cellular level.[13] We found through evidence-based medicine that apatinib had a good effect in some patients with sarcomas (soft tissue sarcomas, osteosarcomas, etc).[14,15] Zhu et al,[16] they found that apatinib showed good efficacy and acceptable safety in patients with metastatic or recurrent sarcomas.